ClinicalTrials.gg
Enrolling by invitationNCT06653400Updated Oct 22, 2026

Combined Ketorolac and Lidocaine Paracervical Block for Office Hysteroscopy

A Phase 1 interventional study of paracervical block and Lidocaine in Abnormal Uterine Bleeding, Analgesia and Paracervical Block, sponsored by Icahn School of Medicine at Mount Sinai. Enrolling by invitation at 1 site in United States. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-22.

Sponsored by Icahn School of Medicine at Mount Sinai · Phase 1, Interventional, and Treatment

How we know

Updated Oct 22, 2026Now Enrolling by invitationStart date moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 43 studies in Metrorrhagia with a site in United States — 8 open to participants now, 9 under way, 1 of them phase 3. Metrorrhagia · United States.

Planned enrollment
20th of 40
60 · median 60
Started
2026
with 5 others
Phase 1
2 of 43
1 open now
Registered
36th of 43
by date

Among the 43 studies in Metrorrhagia with a site in United States, this one is the 20th largest by planned enrollment of the 40 interventional ones that give a count, is one of 6 that started in 2026, is one of 2 in phase 1, and was the 36th registered.

Metrorrhagia

153 studies on the registry are indexed under Metrorrhagia; 34 are open to participants now.

Browse Metrorrhagia studies →

Open to participants now

8 of the 43 studies in Metrorrhagia with a site in United States are open now. Recruiting first, the newest first:

2 more — sign in →

All 8 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 20 Metrorrhagia studies recruiting now, 10 (50%) set no upper age limit and 10 (50%) stop at 75 or younger; 2 take children under 18; 6 take healthy volunteers.

This study: 18 Years and older · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies in Metrorrhagia with a site in United States, or all of them as a file.
02

Study summary

A randomized double-blind placebo controlled trial comparing the effect of a combined ketorolac and lidocaine paracervical block with a standard lidocaine paracervical block on procedure related pain with office hysteroscopies.

Read the detailed description

A randomized double-blind placebo controlled trial comparing the effect of a combined ketorolac and lidocaine paracervical block with a standard lidocaine paracervical block on procedure related pain with office hysteroscopies. Primary Objective: To study the effect of a combined ketorolac and lidocaine paracervical block on procedure related pain with office hysteroscopy. Secondary Objectives: To study the effect of a combined ketorolac and lidocaine paracervical block on patient satisfaction and post procedure pain. To assess for major adverse events with the use of a combined ketorolac and lidocaine paracervical block for office hysteroscopy when compared with a standard lidocaine paracervical block. Primary Endpoint: Pain on a 100 mm visual analogue scale during cervical dilation. Secondary Endpoints: Pain on a 100 mm visual analogue scale during the paracervical block, during the office hysteroscopy, immediately after the hysteroscopy, and 30 minutes after the procedure. Other secondary endpoints include patient satisfaction, frequency of procedure termination, and adverse events. Patients assigned female at birth, booked for office hysteroscopy at Mount Sinai Hospital faculty practice associates. Patients scheduled for office hysteroscopy through seeing a Gynecologist at either 5 E 98th Street Faculty Practice Associates or 1176 5th Avenue Gynecology Practice. 5 E 98th Street primarily cares for privately insured patients, while 1176 5th Avenue cares for a mix of privately insured as well as patients insured with Medicaid. Regardless of recruitment site, all office hysteroscopies will be performed at the 5 E 98th Street facility. A randomized controlled trial designed to investigate if ketorolac added to a paracervical block reduces procedure related pain. Patient will be randomized to a standard paracervical block versus a paracervical block with ketorolac added. The study will be conducted over two years. Patients will be followed for the duration of the two-year study period.

03

Conditions studied

  • Abnormal Uterine Bleeding
  • Analgesia
  • Paracervical Block

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients assigned female at birth,
  • booked for office hysteroscopy at Mount Sinai Hospital faculty practice associates.

Exclusion criteria

Exclusion Criteria:

  • Allergy to ketorolac or non-steroidal anti-inflammatory medications
  • Allergy to lidocaine
  • Presence of thrombocytopenia
  • to lidocaine
  • History of gastritis or gastric ulcer
  • Acute renal failure or chronic renal disease
  • Chronic liver disease
  • History of bleeding diathesis
  • Long term narcotic use
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
60 participants (estimated)

Study arms

  • Placebo comparator
    Lidocaine alone

    Paracervical block will be performed with just lidocaine

    Procedure: paracervical block · Drug: Lidocaine

  • Experimental
    Lidocaine plus ketorolac

    Paracervical block will be performed with lidocaine plus ketorolac

    Procedure: paracervical block · Drug: Lidocaine · Drug: ketorolac

Interventions

  • Procedureparacervical block

    paracervical block with office hysteroscopy

  • Dosage: 20 mL of 1% lidocaine

  • Dosage: 2 mL (30 mg) of ketorolac

06

What researchers measure

Primary outcomes

  1. Pain visual analogue scale (VAS)

    Pain as measured on a 100 mm visual analogue scale (VAS) with cervical dilation. Full scale scored from 0-100, higher score indicates more pain.

    Time frame: during procedure (cervical dilation)

Secondary outcomes

  1. Pain visual analogue scale (VAS)

    Pain as measured on a 100 mm visual analogue scale (VAS). Full scale scored from 0-100, higher score indicates more pain..

    Time frame: with paracervical block, during procedure, immediately after procedure, thirty minutes after the procedure

  2. Patient Satisfaction

    Full scale scored from 0-100, higher score indicates (better or poorer) health outcomes.

    Time frame: with paracervical block, during procedure, immediately after procedure, thirty minutes after the procedure

  3. Frequency of procedure termination

    Number of times of procedure termination

    Time frame: with paracervical block, during procedure, immediately after procedure, thirty minutes after the procedure

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Yes — All of the individual participant data collected during the trial, after deidentification.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Immediately following publication. No end date.

Access criteria: Anyone who wishes to access the data. To achieve aims in the approved proposal. Proposals may be submitted up to 36 months following article publication. After 36 months the data will be available in our University's data warehouse but without investigator support other than deposited metadata.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Jul 2026 (actual). Primary completion is estimated for Dec 2026, 5 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 22, 2026: start Feb 2025 → Jul 2026, primary completion Sep 2026 → Dec 2026 and completion Sep 2026 → Dec 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 20, 2024
First posted
Oct 22, 2024
StartActual
Jul 1, 2026was Feb 2025
Primary completionEst.
Dec 31, 2026was Sep 2026
CompletionEst.
Dec 31, 2027was Sep 2026
Last update
Oct 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Enrolling by invitation
changed Oct 22, 2026
Start date
Feb 27, 2025→Jul 1, 2026
Oct 22, 2026
Primary completion
Sep 1, 2026→Dec 31, 2026
Oct 22, 2026
Study completion
Sep 1, 2026→Dec 31, 2027
Oct 22, 2026
Contact
No study contact listed any more: removed k•••@mssm.edu · •••4500; removed v•••@mssm.edu
Oct 22, 2026
Show all 1 update
  1. Oct 22, 2026
    Recruiting→Enrolling by invitation
    Start date Feb 27, 2025→Jul 1, 2026
    Primary completion Sep 1, 2026→Dec 31, 2026
    Study completion Sep 1, 2026→Dec 31, 2027
    Contact No study contact listed any more: removed k•••@mssm.edu · •••4500; removed v•••@mssm.edu
    + 2 other changes: verification date and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06653400
Responsible party
Charles Ascher-Walsh (Professor, Icahn School of Medicine at Mount Sinai) — Principal investigator
First posted
Oct 22, 2024
Start date
Jul 1, 2026
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Oct 22, 2026

Study contacts

Charles Ascher-Walsh, MD
principal investigator · Icahn School of Medicine at Mount Sinai

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ketorolac

Start the discussion